- Home
- EVGN vs RDHL Comparison
EVGN vs RDHL Comparison
Compare EVGN & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVGN
- RDHL
- Stock Information
- Founded
- EVGN 1999
- RDHL 2009
- Country
- EVGN Israel
- RDHL Israel
- Employees
- EVGN N/A
- RDHL N/A
- Industry
- EVGN Agricultural Chemicals
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- EVGN Industrials
- RDHL Health Care
- Exchange
- EVGN Nasdaq
- RDHL Nasdaq
- Market Cap
- EVGN 9.7M
- RDHL 8.6M
- IPO Year
- EVGN N/A
- RDHL N/A
- Fundamental
- Price
- EVGN $1.35
- RDHL $6.50
- Analyst Decision
- EVGN Strong Buy
- RDHL
- Analyst Count
- EVGN 1
- RDHL 0
- Target Price
- EVGN $12.00
- RDHL N/A
- AVG Volume (30 Days)
- EVGN 58.6K
- RDHL 21.6K
- Earning Date
- EVGN 11-21-2024
- RDHL 01-03-2025
- Dividend Yield
- EVGN N/A
- RDHL N/A
- EPS Growth
- EVGN N/A
- RDHL N/A
- EPS
- EVGN N/A
- RDHL N/A
- Revenue
- EVGN $7,478,000.00
- RDHL $3,707,000.00
- Revenue This Year
- EVGN $90.35
- RDHL $224.90
- Revenue Next Year
- EVGN $38.71
- RDHL $82.69
- P/E Ratio
- EVGN N/A
- RDHL N/A
- Revenue Growth
- EVGN 30.69
- RDHL N/A
- 52 Week Low
- EVGN $1.20
- RDHL $6.00
- 52 Week High
- EVGN $10.40
- RDHL $40.50
- Technical
- Relative Strength Index (RSI)
- EVGN 36.47
- RDHL 38.21
- Support Level
- EVGN $1.20
- RDHL $6.00
- Resistance Level
- EVGN $1.49
- RDHL $7.30
- Average True Range (ATR)
- EVGN 0.12
- RDHL 0.51
- MACD
- EVGN 0.01
- RDHL -0.09
- Stochastic Oscillator
- EVGN 35.71
- RDHL 21.10
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.